MIRIS
30.9.2020 07:02:12 CEST | Business Wire | Press release
«Be the change you want to see in the world, » is a well-worn cliché. However, most of us feel overwhelmed in the face of the climate and environmental challenges. Instead of giving in, Cape Town-based Danielle Laity and her team decided to do something. They’ve started a new community: Aurora Sustainability .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005910/en/
“In Cape Town, we feel the need for a more sustainable and fairer world every day. Food security is an issue, the predominantly fossil fuel based electrical grid is under strain and climate change will only exacerbate these problems” says Danielle Laity.
On the Aurora community platform, anyone can log on and take a quick quiz that tells you the size of your carbon footprint. The intention is not to compete or compare yourself to others; it’s to get a measure of how sustainable you are today, and then receive the information and inspiration needed to make sustainable lifestyle changes.
An overwhelming problem
An ocean filled with plastic, carbon emissions out of control despite major international agreements, and every year the world's population increases by about 1 percent; approximately 80 million people.
In South Africa these problems are felt even more precariously than if, for example, one lives in Norway where the effects may not be seen in day to day life.
The climate crisis has been created by the sum of all human action, so if each of us does something, we can contribute a little to solving the problem.
Aurora Sustainability is now beta testing its second version, and they have already gained over 10,000 users. It was launched in South Africa, but they are now rolling it out in Norway as their second country.
“Where one individual may seem powerless, 10,000 people who take action is starting to look like a movement, and we are only getting started,” says Laity.
Aurora Sustainability will use the network effect to change the world
When a network effect is present, the value of a product increases according to the number of others using it. Our users will be able to tell each other about changes they have made, and point each other towards greener choices.
“It’s possible for consumers to drive industry if we come together to make a difference,” says Laity.
When you take the quiz, you get an Aurora score divided into five areas. The higher the score, the more sustainable you are. The five areas measured are energy use, transport, food, other consumption and investments. If, for example, you start cycling to work, then you will be able to see what change this makes to your CO2 footprint.
In your dashboard you will have a complete overview of how sustainable your lifestyle is (or not). For many, it does not make much sense to talk about kilograms of CO2 saved, therefore Aurora also makes comparisons to units that are more specific. For example, how many loads of washing you have saved.
Her ambitions for Aurora Sustainability are grand: “We will be the community for everyone who wants to make a difference. Those who don’t want to wait for politicians to make all the choices, but who make concrete choices in their everyday lives. There are enough people to be able to make a big difference here and now,” says Laity.
Aurora community is a Miris initiative; the disruptive, greentech, real estate company.
Join the Aurora community on Facebook, Instagram South Africa and Instagram Norway , and take the quiz here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005910/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
